Stockscreener 앱 받기
0.2411
2.16%
0.0051
시간 외 거래:
.25
0.0089
+3.69%
전일 마감가:
$0.236
열려 있는:
$0.2409
하루 거래량:
3.56M
Relative Volume:
0.40
시가총액:
$43.01M
수익:
$5.21M
순이익/손실:
$-26.35M
주가수익비율:
-0.1878
EPS:
-1.2835
순현금흐름:
$-20.84M
1주 성능:
-18.19%
1개월 성능:
-17.66%
6개월 성능:
-41.99%
1년 성능:
-52.82%
1일 변동 폭
$0.23
$0.2467
1주일 범위
$0.23
$0.2762
52주 변동 폭
$0.1634
$2.08
Plus Therapeutics Inc Stock (PSTV) Company Profile
명칭
Plus Therapeutics Inc
전화
737.255.7194
주소
4200 MARATHON BLVD., AUSTIN, TX
Compare PSTV vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PSTV
Plus Therapeutics Inc
|
0.2411 | 42.10M | 5.21M | -26.35M | -20.84M | -1.2835 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-03 | 개시 | Lake Street | Buy |
| 2025-09-03 | 업그레이드 | D. Boral Capital | Hold → Buy |
| 2025-03-17 | 개시 | D. Boral Capital | Buy |
| 2021-01-25 | 개시 | Ladenburg Thalmann | Buy |
| 2020-10-16 | 개시 | Maxim Group | Buy |
Plus Therapeutics Inc 주식(PSTV)의 최신 뉴스
PSTV Analyst Rating: D. Boral Capital Maintains Buy Rating | PST - GuruFocus
Plus Therapeutics Presents Analysis Showing CNSide May Reduce Leptomeningeal Metastases Costs by 40% - National Today
Plus Therapeutics (PSTV) Study Highlights Cost Benefits of Early LM Detection - GuruFocus
Plus Therapeutics Study Shows Early Detection Can Reduce Healthcare Costs - Intellectia AI
Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40% - The Manila Times
Late-stage LM care can top $100,000 a month, Plus analysis says - Stock Titan
Analysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Plus Therapeutics (PSTV) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Aclaris Therapeutics (ACRS) and Plus Therapeutics (PSTV) - The Globe and Mail
Plus Therapeutics Sets 2026 Virtual Annual Stockholder Meeting - The Globe and Mail
Plus: Q4 Earnings Snapshot - theheraldreview.com
Plus Therapeutics (PSTV) Beats EPS Expectations Despite Revenue Decline - GuruFocus
Plus Therapeutics (PSTV) Surpasses Q4 Revenue Expectations - GuruFocus
Plus Therapeutics Reports 2025 Results, Advances CNSide Commercial Rollout and REYOBIQ Clinical Program with 2026 Milestones - Minichart
PLUS THERAPEUTICS, INC. Files Form 8-K with SEC Detailing Shareholder Director Nomination Procedures and Company Information - Minichart
Plus Therapeutics, Inc. 2025 Annual Report: Precision Radiopharmaceuticals and CNS Cancer Innovations - Minichart
Plus Therapeutics (PSTV) Reports Break-Even Earnings for Q4 - Yahoo Finance
Plus: Q4 Financial Overview - Bitget
Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ Clinical Program and CNSide Commercial Rollout - Bitget
Plus Therapeutics 2025 net loss widens - TradingView
[8-K] PLUS THERAPEUTICS, INC. Reports Material Event | PSTV SEC FilingForm 8-K - Stock Titan
Plus Therapeutics 10-K: $5.21M Grant Revenue, Net Loss $0.29 EPS - TradingView
Plus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Plus Therapeutics (NASDAQ: PSTV) updates CNS oncology pipeline and CNSide - Stock Titan
Plus Therapeutics (PSTV) widens 2025 loss but strengthens cash and CNS programs - Stock Titan
Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ™ Clinical Program and CNSide® Commercial Rollout - The Manila Times
Inside Plus Therapeutics' 2026 brain cancer drug and spinal fluid test plans - Stock Titan
PSTV Earnings History & Surprises | EPS & Revenue Results | PLUS THERAPEUTICS INC (NASDAQ:PSTV) - ChartMill
Plus Therapeutics drops 5%, files prospectus for 17M share secondary offering - MSN
Can Plus Therapeutics Inc. stock deliver strong Q4 earningsEarnings Miss & Verified Short-Term Trading Plans - Naître et grandir
[RW] PLUS THERAPEUTICS, INC. SEC Filing - Stock Titan
PSTV SEC FilingsPlus Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
138,897,548 Common Stock of Plus Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 28-FEB-2026. - marketscreener.com
Certain Warrants of Plus Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 28-FEB-2026. - marketscreener.com
Certain Restricted Stock Units of Plus Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 28-FEB-2026. - marketscreener.com
Lake Street Sticks to Their Buy Rating for Plus Therapeutics (PSTV) - The Globe and Mail
Plus Therapeutics (PSTV) CFO granted RSUs and stock options package - Stock Titan
PLUS Therapeutics (PSTV) CEO receives large RSU and stock option grants - Stock Titan
PLUS THERAPEUTICS, Inc.Common Stock (NQ: PSTV - The Chronicle-Journal
Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ - Bitget
Plus Therapeutics, Inc. Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ - marketscreener.com
Plus Therapeutics (PSTV) Gains New CPT Code for Innovation in Br - GuruFocus
Plus Therapeutics announces new Category III CPT code - marketscreener.com
Plus Therapeutics Receives AMA Approval for New CPT Code for REYOBIQ in Treatment of CNS Cancers - Quiver Quantitative
Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ™ - GlobeNewswire
PSTV Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Value Recap: Is Plus Therapeutics Inc stock undervalued right nowWeekly Stock Summary & Short-Term Swing Trade Alerts - baoquankhu1.vn
Aug EndMonth: Is Plus Therapeutics Inc stock undervalued right nowMarket Weekly Review & Comprehensive Market Scan Reports - baoquankhu1.vn
Is Plus Therapeutics Inc. in accumulation or distribution phase2025 Retail Activity & Short-Term Trading Opportunity Alerts - mfd.ru
Plus Therapeutics Updates Executive Compensation, Approves 2025 Bonuses - The Globe and Mail
Aug Gainers: Can Plus Therapeutics Inc stock double in the next yearJuly 2025 Drop Watch & Stock Timing and Entry Methods - baoquankhu1.vn
Is Plus Therapeutics Inc. stock showing strong momentumGlobal Markets & Trade Opportunity Analysis - mfd.ru
Plus Therapeutics Inc (PSTV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):